Brussels: The European Commission’s most ambitious rewrite of its merger rulebook in more than twenty years has just cleared a milestone, with the public consultation on the draft Merger Assessment Guidelines closing on 26 June. What emerges from the responses now landing in Brussels will shape how thousands of deals are judged for the rest of the decade, and the early reaction from lawyers, economists and start-up founders suggests the stakes are widely understood.
The headline shift is conceptual. For years the Commission asked a fairly narrow question about whether a tie-up would lessen competition in a defined market today. The draft published on 30 April broadens that lens to capture harms that only materialise later. Three new theories of harm sit at the centre: the loss of future investment and expansion, the loss of innovation competition, and the entrenchment of an already dominant position. A merger could now be blocked even where classical foreclosure is absent, if it raises structural barriers across a core market and the products clustered around it.
The most debated piece is the treatment of so-called killer acquisitions, where a large incumbent buys a young rival precisely to stop it maturing into a threat. The draft elevates lost innovation to a standalone concern, assessed by looking at the parties’ research pipelines, their capacity to innovate and how directly their projects compete. For pharmaceutical and technology buyers that habitually acquire early-stage targets, the message is that a thin market-share argument may no longer settle the matter.
Yet the Commission has paired the tougher stance with a notable concession. A new ‘innovation shield’ is meant to keep the vast majority of start-up purchases outside the danger zone. Under it, an acquisition of a small innovative target is presumptively safe where there is no research overlap, or where at least three other firms with comparable competitive potential remain independently active in the same space and the parties hold low market shares. The clarification that a deal counts as a killer acquisition only when a dominant firm absorbs a genuinely nascent rival capable of becoming significant is designed to reassure venture investors who feared every exit would invite scrutiny.
Critics are not uniformly soothed. Some practitioners warn that the new theories rely on predictive judgements about innovation that are inherently uncertain, handing case teams wide discretion and making outcomes harder to forecast. Deal-makers value predictability above almost everything, and a framework that asks regulators to weigh hypothetical future competition cuts against that. Others counter that the old approach repeatedly let consequential acquisitions through unexamined, and that adapting to fast-moving digital and life-science markets requires exactly this kind of forward look.
There is also a counterweight that merging companies will welcome. The draft gives greater room to argue that a transaction delivers benefits, including efficiencies and stronger capacity to invest, which can offset competitive concerns. That two-sided character, sharper teeth alongside broader defences, is what makes the package genuinely new rather than simply stricter.
With the consultation now shut, the Commission has said it will finalise its review in the fourth quarter and aims to adopt the guidelines in their final form late this year or early in 2027. Between now and then, the responses gathered in Brussels will test whether the balance struck on paper can survive contact with the deals it is meant to police.
